Respiratory Motion, a Waltham, Mass.-based medical device company, raised $5.8m in Series B financing.
The round was led by Easton Capital, with participation from early investors. In conjunction with the funding, John Friedman, Managing Director of Easton Capital, will join the company’s Board of Directors.
The company intends to use the funds to expand its sales and marketing efforts.
Led by Jenny Freeman, CEO, and newly appointed vice president of sales and marketing John Geisel, Respiratory Motion provides ExSpiron, an FDA-approved respiration monitoring system, which leverages advances in digital processing and algorithmic programming to improve patient flow in the post-operative suites.
According to a note, the company expects to raise up to an additional $3m of capital in the current round.